Table 2.
New Therapies for PCa.
| Therapy | Type | CSPC/CRPC | FDA Approval |
Monotherapy /Combinations |
|---|---|---|---|---|
| Parpi | OLAPARIB | CRPC | YES (in selected population) |
Monotherapy Combinations under investigation: + IMMUNOTHERAPY + ANTIANDROGEN+ NEW THERAPIES |
| RUCAPARIB | CRPC | YES (in selected population; phase III study is currently underway) |
||
| NIRAPARIB | CRPC | NO (clinical development program) |
||
| TALAZOPARIB | CRPC | |||
| Immunotherapy | DC VACCINES SIPULEUCEL-T | CRPC | YES | Monotherapy |
| ANTI CTLA-4 | CRPC | NO (clinical development program) |
Combinations under investigation: + PARPi + ANTIANDROGENPembrolizumab in monotherapy (combinations under investigation) |
|
| PD-1/PD-L1 INHIBITORS |
CRPC | YES (Pembrolizumab in selected population) |
||
| NO (other ihibitors in clinical development program) | ||||
|
Anti-PSMA
Therapy |
RADIONUCLIDES | CSPC/CRPC | NO (clinical development program) |
Monotherapy |
| CAR-T CELLS | ||||
| BISPECIFIC T-CELL ANTIBODIES |
Key: CRPC: castration-resistant prostate cancer; CSPC: castration-sensitive prostate cancer; DC: dendritic cell; PARPi: PARP inhibitors; PSMA: prostate-specific membrane antigen.